相关实验视频

Updated: Jun 1, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

雷梅西维尔对SARS-CoV-2进化的影响 in vivo

Ted Ling-Hu^1,2, Lacy M Simons^1,2, Estefany Rios-Guzman^1,2

¹Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

|January 21, 2025

概括

雷梅西维尔治疗没有显著改变SARS-CoV-2遗传分歧. 然而,它选择了像nsp12 G671S这样的突变,可能增加病毒适应性并帮助克服抗病毒压力.

科学领域:

病毒学病毒学
分子生物学分子生物学
基因组学就是基因组学.

背景情况:

雷梅西维尔对SARS-CoV-2进化的体内影响尚不清楚.
抗病毒疗法可以对病毒种群施加选择性压力.

研究的目的:

研究雷梅西维尔对住院患者的SARS-CoV-2多样化和多样性的影响.
为了识别特定的突变,选择通过remdesivir治疗.

主要方法:

回顾性队列研究,分析对患者样本的全基因组测序 (remdesivir前后).
治疗和未治疗患者组之间的遗传分歧和少数变体分析的比较.
在接受雷梅西维尔的第二组患者中进行验证.

主要成果:

雷梅西维尔治疗组和对照组之间整体遗传差异没有显著差异.
在特定地点进行优先多样化,包括少数变异,在治疗后.
对nsp12 G671S突变的强有力的选择,与增强的病毒适应性和nsp12:V792I.I.的丰富有关.

结论:

雷梅西维尔治疗可能间接选择具有增加复制性适应性的SARS-CoV-2变种.
抗病毒疗法可以推动特定病毒突变的进化.
了解这些进化动态对于抗病毒耐药性监测至关重要.

关键词:

在 COVID-19 疫情中,药物治疗是药物治疗.治疗方法治疗方法

更多相关视频

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

相关概念视频

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...